Pfizer, Merck get FDA nod for Bavencio plus Inlyta to treat advanced RCC

This article was originally published here

The approval was based on data from the phase III Javelin Renal 101 study, in which the combination significantly improved median progression-free survival (PFS) compared against sunitinib by

The post Pfizer, Merck get FDA nod for Bavencio plus Inlyta to treat advanced RCC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply